Photo by polarmermaid from unsplash
Key Points Combination therapy with pembrolizumab and rituximab was well tolerated in patients with relapsed/refractory follicular lymphoma. In this single-arm, phase 2 study, the overall response rate was 67%, with… Click to show full abstract
Key Points Combination therapy with pembrolizumab and rituximab was well tolerated in patients with relapsed/refractory follicular lymphoma. In this single-arm, phase 2 study, the overall response rate was 67%, with 50% complete response and median PFS of 12.6 months.
Keywords:
refractory follicular;
relapsed refractory;
combination;
follicular lymphoma;
rituximab
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!